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Available online 8 June 2016Objective: Here we tested the effect of combined antiretroviral therapy (cART) on deviant electroencephalo-
graphic (EEG) source activity in treatment-naïve HIV individuals.
Methods: Resting state eyes-closed EEG data were recorded before and after 5 months of cART in 48 male HIV
subjects, whowere naïve at the study start. The EEG data were also recorded in 59 age- and sex-matched healthy
subjects as a control group. Frequency bands of interest included delta, theta, alpha1, alpha2 and alpha3, based on
alpha frequency peak speciﬁc to each individual. They also included beta1 (13–20 Hz) and beta2 (20–30 Hz).
Low-resolution brain electromagnetic tomography (LORETA) estimated EEG cortical source activity in frontal,
central, temporal, parietal, and occipital regions.
Results: Before the therapy, theHIV group showedgreater parietal delta source activity and lower spatially diffuse
alpha source activity compared to the control group. Thus, the ratio of parietal delta and alpha3 source activity
served as an EEGmarker. The z-score showed a statistically deviant EEG marker (EEG+) in 50% of the HIV indi-
viduals before therapy (p b 0.05). After 5 months of cART, delta source activity decreased, and alpha3 source ac-
tivity increased in the HIV subjects with EEG+ (about 50% of them showed a normalized EEG marker).
Conclusions: This procedure detected a deviant EEGmarker before therapy and its post-therapy normalization in
naïve HIV single individuals.
Signiﬁcance: The parietal delta/alpha3 EEGmarkermay be used tomonitor cART effects on brain function in such
individuals.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Alpha rhythms1. Introduction
Infection with human immunodeﬁciency virus (HIV) causes neuro-
pathological changes as well as neurological and neuropsychological
symptoms in most (i.e. N50%) subjects over time (McArthur, 1987;
Chavanet et al., 1988; Gastaut et al., 1989; Chalmers et al., 1990; Fauci
and Lane, 1998; Williams et al., 2002, 2012; Selnes, 2005; Anthonynd Pharmacology, University of
.
loni).
. This is an open access article underand Bell, 2008; Antinori et al., 2007; Roberts et al., 2010). Fortunately,
combined antiretroviral therapy (cART) mitigates these effects of HIV
on brain function (Clifford, 2008), thanks to the attenuation of viral
load (VL) and increased CD4 cell counts (Graham et al., 1992;
Hammer et al., 1997; Hunt et al., 2003;Williams et al., 2012). However,
the prevalence of HIV patients with neurological and neuropsychologi-
cal symptoms remains relatively high (Cysique et al., 2009; Sevigny et
al., 2004). One of the reasons for this situation is the lack of biomarkers
suitable for monitoring the brain function effects of HIV and cART, espe-
cially for the personalized clinical management of HIV and therapy
monitoring on an individual-, rather than population-level.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Means (±standard error, SE) of the personal and/or clinical features of healthy and treat-
ment-naïveHIVmale individuals of the present study. The third column reports the results
of t-tests (p b 0.05, one-tailed) comparing thesemean values between the two groups (i.e.
Healthy vs. treatment-naïve HIV). Legend: MMSE=Mini Mental State Examination; CD4
= CD4 lymphocyte count; VL = HIV-RNA viral load in the blood.
Healthy Naïve HIV p values
N 59 48
Age (years) 39.0 (±2.2 SE) 39.4 (±1.6 SE) n.s.
Education (years) 14.8 (±0.5 SE) 13.2 (±0.4 SE) p = 0.01
MMSE score 29.6 (±0.1 SE) 28.4 (±0.3 SE) p = 0.0005
CD4 count (cells/μl) – 374.2 (±33.3 SE)
VL (copies/ml) – 120,166.7 (±32,057.9 SE)
145C. Babiloni et al. / NeuroImage: Clinical 12 (2016) 144–156Resting state electroencephalographic (EEG) rhythms are a readily
observed and quantiﬁed functional feature of the brain, and represent
promising candidates for disease biomarkers. EEG rhythms reﬂect neu-
rophysiological mechanisms of cortical neural synchronization related
to theﬂuctuation of cortical arousal during changes in states of vigilance
(Babiloni et al., 2011a). It can be hypothesized that quantitative EEG
biomarkers can contribute to a preliminary instrumental assessment
of HIV subjects, as well as to understanding the neurophysiological
mechanisms underlying HIV's effects on brain function. In this line, pre-
ceding studies have shown the topography of resting state eyes-closed
EEG rhythms in groups of HIV individuals. Compared to control groups
of healthy subjects, HIV groups exhibited decreased posterior alpha (8–
13 Hz) power density (Gruzelier et al., 1996; Baldeweg and Gruzelier,
1997; Baldeweg et al., 1997). This effect preceded cognitive and neuro-
logical impairment, was associated with changes in psychiatric status,
and was normalized by cART (Baldeweg and Gruzelier, 1997;
Baldeweg et al., 1997). In addition, deviant theta (4–7 Hz) and alpha
power density was associated with mood and immune status (i.e. CD4
counts) in a group of asymptomatic HIV subjects (Gruzelier et al., 1996).
To overcome partially head volume conduction effects blurring the lo-
calization of the cortical generators of resting state scalp EEG rhythms, our
research group has used a popular freeware called low-resolution brain
electromagnetic tomography (LORETA; Pascual-Marqui and Michel,
1994). Results were quite promising at the group level. Compared to
healthy subjects, naïveHIV subjectswere characterized by greater activity
of central and parietal delta sources (b4 Hz), as well as lower alpha (8–
12 Hz) sources in widespread cortical regions (Babiloni et al., 2012).
These differences in alpha sources were less marked in HIV subjects
experiencing cART for at least 12 months (Babiloni et al., 2014). Further-
more, they showed normal delta source activity (Babiloni et al., 2014).
This beneﬁcial effect of cART on brain function was conﬁrmed by a longi-
tudinal study in which EEG rhythms were recorded before and after
5 months of cART in naïve HIV subjects (Babiloni et al., 2015a).
More recently, we have tested a simple statistical procedure based
on the computation of z-score (p b 0.05, one-tailed) to identify treat-
ment-naïve HIV male individuals having deviant activity of cortical
(LORETA) sources of resting state eyes-closed delta and alpha rhythms
(Babiloni et al., 2015b). The ratio of the activity between parietal delta
and high-frequency alpha sources served as an EEG marker of interest.
The z-score of this EEG marker allowed the identiﬁcation of a relatively
high percentage (about 40–50%) of treatment-naïve HIV individuals
with a statistical difference of EEG activity (p b 0.05, one-tailed). These
results suggested that this EEG marker might enrich the instrumental
assessment of HIV effect on brain function in treatment-naïve HIV
male individuals. However, the study could not clarify the extent to
which the mentioned z-score procedure is sensitive to the impact of
cART on naïve HIV individuals (no follow-up). Therefore, we sought to
address this unanswered question in the present study. We hypothe-
sized that the naïveHIV individualswith z-scores indicating that normal
EEG source activity before the therapy would show a global stability of
this activity after 5 months of cART. In other words, we expected their
EEG rhythms to remain relatively unchanged and within the previously
determined levels of normalcy even after treatment. In contrast, those
individuals with z-scores indicating deviant EEG source activity before
treatment were expected to show beneﬁcial effects of cART on this ac-
tivity (i.e. a normalization of EEG source activity) at the follow-up.
2. Methods
2.1. Subjects
This study included EEG and clinical data of 48 naïve HIV male sub-
jects (mean age 39.4 years ± 1.6 standard error, SE), recruited at Uni-
versity S. Andrea Hospital and Tor Vergata Hospital of Rome (Italy). It
also included EEG and clinical data of an age-matched control group of
59 cognitively normal male subjects (Healthy; mean age 39 years ±2.2 SE), selected from a university archive to obtain the best matching
of age and gender between the two groups.
All experiments were performedwith thewritten informed consent
of eachparticipant andwith the approval by the local ethical committee,
in line with the Code of Ethics of theWorld Medical Association (Decla-
ration of Helsinki) and the standards established by theAuthor's Institu-
tional Review Board.
2.2. Diagnostic criteria
All participants received laboratory exams for the conﬁrmation of
the HIV serostatus. These exams included HIV RNA viral load, Complete
Blood Count (CBC), Treponema screening, CD4 lymphocyte count and
percent, toxoplasmosis and cytomegalovirus antibody titers, HBV–HCV
screening, serum protein, renal and liver function, and albumin. Toxico-
logical analyses on urine samples controlled for the use of cocaine, opi-
ates, amphetamine, and marijuana. No naïve HIV subjects showed CD4
counts compatible with a diagnosis of full-blown AIDS. A Computerized
Diagnostic Interview Schedule interview (i.e. Version IV, CDIS-IV) con-
trolled for DSM-IV Axis I and II disorders. The naïve HIV subjects com-
pleted questionnaires or brief interviews that assessed their medical
history, medication use, parental psychopathology, psychiatric symp-
toms, demographics, drug and alcohol use, and cognitive status. Fur-
thermore, neuropsychological tests assessed memory, language,
executive function/attention, and visuo-construction abilities. Memory
was evaluated by the Prose Memory Test delayed recall of a story
(Spinnler and Tognoni, 1987). Language was assessed by 1-minute ver-
bal ﬂuency for letters (Novelli et al., 1986) and 1-minute verbal ﬂuency
for fruits, animals or car trades (Novelli et al., 1986). Executive function
and attention were evaluated by the Trail Making Test part A and B
(Reitan, 1958). Finally, Mini-Mental State Examination (MMSE) tested
global basic cognitive functions (Folstein et al., 1975). Table 1 reports in-
formation about personal and clinical characteristics of the healthy and
naïveHIV subjects of thepresent study. An independent t-test evaluated
the presence or absence of statistically signiﬁcant differences between
the two groups (i.e. Healthy and naïve HIV) for age, education, and
MMSE score (p b 0.05). Results showed a statistically signiﬁcant differ-
ence in theMMSE score (p= 0.0005), which was higher in the Healthy
group than in the naïve HIV group. Furthermore, there was a higher ed-
ucation in the Healthy group than in the naïve HIV group (p= 0.01). In
contrast, no statistically signiﬁcant difference was found for age
(p N 0.9). Therefore, educationwasused as a covariate in the subsequent
statistical comparisons between the Healthy and the naïve HIV groups.
Exclusion criteria included mental retardation, intelligent quotient
(IQ) score lower than 70, seizures, acute illness, and neurosurgery.
These criteria also includedhistory of head injurywith loss of conscious-
ness (Bauer and Shanley, 2006) and major neurological and psychiatric
disorders such as schizophrenia or bipolar disorder (Diagnostic and Sta-
tistical Manual of Mental Disorders fourth edition, DSM-IV). Naïve HIV
subjects were excluded for medical disorders such as chronic obstruc-
tive pulmonary disease, hypertension, hepatic encephalopathy, ocular
disorders, Type 1 diabetes, and cirrhosis. They were also excluded in
146 C. Babiloni et al. / NeuroImage: Clinical 12 (2016) 144–156case of a positive urine toxicology or breathalyzer tests. They were also
excluded for a recent (past year) dependence upon alcohol, cocaine or
opiates.
All healthy subjects underwent cognitive screening as well as phys-
ical and neurological examinations. They were neither affected by
chronic systemic illnesses, major neurological or psychiatric diseases
nor assumed psychoactive drugs. None of them had a major depression
based on a clinical exam.
2.3. EEG recordings
Resting state eyes-closed EEG data were collected by 0.3–70 Hz
bandpass, 19 electrodes placed according to 10–20 System (i.e. O1, O2,
P3, Pz, P4, C3, Cz, C4, T3, T5, T4, T6, Fp1, Fp2, F7, F3, Fz, F4, and F8) and
cephalic reference. To monitor eye movements, the horizontal and ver-
tical electrooculograms (EOGs, 0.3–70 Hz bandpass) were also collect-
ed. EEG and EOG data were recorded for 5 min in continuous mode
with 256Hz sampling rate. In thenaïveHIV subjects, these datawere re-
corded at baseline (pre-treatment; T0) and after 5months of cART (T5).
The recordings were carried out in the late morning. To control the
state of vigilance, an expert continuously monitored subject's behavior
and EEG–EOG signals. The subject was verbally alerted in the case of be-
havioral or EEG drowsiness. Speciﬁcally, the experimenter monitored
the appearance of “tonic” theta rhythms, K-complexes and sleep spin-
dles (behavior in the control subjects). Of note, a low percentage of sub-
jects (much less than 10%) required such verbal prompt.
The 5 min duration of the EEG recording allowed the comparison of
the present resultswith several previous EEG studies in neurological pa-
tients using recording periods shorter or equal to 5 min (Babiloni et al.,
2004, 2006b, 2007, 2012, 2014, 2015a,b; Buchan et al., 1997; Pucci et al.,
1999; Rodriguez et al., 2002; Szelies et al., 1999) or about 1 min (Dierks
et al., 1993, 2000); longer EEG epochswould have reduced data variabil-
ity but increased risks for dropping vigilance and arousal.
2.4. Preliminary EEG data analysis
The collected EEG data were off-line fragmented in consecutive pe-
riods (epochs) of 2 s. An automatic computerized procedure preliminar-
ily identiﬁed the EEG epochs with ocular, muscular, and other types of
artifacts (including verbal prompts). EEG epochs with sporadic blinking
artifacts (threshold of ±50 μV) were much less than 10% of the total.
These epochs were corrected by an autoregressive method (Moretti et
al., 2003). Afterwards, two independent experimenters (i.e. G.N and
S.C.), blind to the diagnosis, manually conﬁrmed the EEG epochs accept-
ed for a further analysis. The EEG epochs with an incomplete removal of
the blinking or other artifacts weremanually rejected. Of note, a control
analysis showed no difference (p N 0.05) in the percentage of the eyes
blinks between the Healthy and the naïve HIV group (exact Fisher
test, p N 0.05).
2.5. Spectral analysis of the EEG data
A spectrum analysis (FFT, Welch technique, Hanning windowing
function with no phase shift) computed power density of EEG rhythms
with frequency resolution of 0.5 Hz. Absolute EEG power density values
were normalized by the following procedure: 1) mean EEG power den-
sitywas computed for all frequency bins and all electrodes; and 2) abso-
lute power density values for all frequency bins at each electrode were
divided by the mean power density computed at 1). The EEG frequency
bands of interest were determined based on the identiﬁcation of EEG
power density peak in the range of alpha rhythms (e.g. 7–13 Hz) in
any subject, the so-called individual alpha frequency peak (IAF peak;
Klimesch et al., 1998). In this line, the EEG frequency bands of interest
were deﬁned as follows: (i) delta, IAF−8 Hz to IAF−6 Hz; (ii) theta,
IAF−6 Hz to IAF−4 Hz; (iii) alpha 1, IAF−4 Hz to IAF −2 Hz; (iv)
alpha 2, IAF−2 Hz to IAF; and (v) alpha 3, IAF to IAF +2 Hz. Of note,the mean IAF peak was 10.1 Hz (±0.1 SE) in naïve HIV group and 10.2
(±0.1 SE) in the Healthy group. No statistical difference in the IAF
peakwas observed between the two groups (Student's t-test one-tailed,
p N 0.05). For higher EEG band frequencies, standard ﬁxed frequency
bands were selected, as a beta power density peak was not clearly de-
tectable in all subjects. Speciﬁcally, they were deﬁned as beta 1 (13–
20 Hz) and beta 2 (20–30 Hz).
2.6. Cortical (LORETA) source of EEG rhythms
The LORETA software (http://www.unizh.ch/keyinst/NewLORETA/
LORETA01.htm) was used for the estimation of the activity (i.e. neural
current density) of cortical sources of the EEG rhythms
(Pascual-Marqui and Michel, 1994, Pascual-Marqui et al., 1999, 2002).
LORETA is a functional imaging technique belonging to a family of linear
inverse solution procedures likeminimumnorm solution,weighted res-
olution optimization or weighted minimum norm solution, which
model 3D distributions of EEG sources (Valdès et al., 1998;
Pascual-Marqui et al., 1999; Phillips et al., 2002; Yao and He, 2001). Of
note, LORETA has been successfully used in recent EEG studies on neu-
rological subjects by the present experimental set up of the present
study (Dierks et al., 2000; Babiloni et al., 2004, 2006b, 2007, 2012,
2014, 2015a,b). Results of these studies suggest that LORETA provides
reliable estimates of distributed cortical source activity of resting state
EEG rhythms collected from 19 electrodes placed according to 10–20
montage (Anderer et al., 2000, 2003, 2004; Mulert et al., 2001;
Winterer et al., 2001; Babiloni et al., 2004, 2006b, 2007, 2012, 2014,
2015a,b; Veiga et al., 2003). Indeed, these resting state EEG rhythms
are generated by largely distributed cortical sources whose EEG activity
can be recorded by 10–20 system without spatial aliasing. Overall, the
present results suggest that topographicallywidespread cortical sources
of resting state delta and alpha rhythms reﬂect neurophysiologic abnor-
malities in naïve HIV subjects, at least at a group level.
LORETA provides 3D solutions to the EEG inverse problem (i.e.
LORETA solutions). The LORETA solutions estimate the neural current
density into a head model formed by 3 spherical compartments
representing the electrical properties of the scalp, skull, and brain. The
brain compartment is co-registered to the Talairach probability brain
atlas (Talairach and Tournoux, 1988). It includes cortical gray matter
and hippocampus, digitated in the Brain Imaging Center of Montreal
Neurological Institute. The brain compartment is constituted by
2394 voxels with 7 mm of spatial resolution. Any voxel contains an
equivalent current dipole, which is ﬁxed as position and orientation.
The LORETA solutions estimate the current intensity of all equivalent
current dipoles of the brain compartment to explain scalp EEG power
density at scalp electrodes (Pascual-Marqui and Michel, 1994).
Solutions of the EEG inverse problem are under-determined and ill-
conditioned, when the number of spatial samples (electrodes) is lower
than that of the unknown samples (current density at each voxel). For
this reason, the cortical LORETA solutions (i.e. estimates of dipole cur-
rent density at any voxel) predicting scalp EEG spectral power density
were regularized to estimate maximally-smoothed rather than
circumscribed EEG source activity (Pascual-Marqui and Michel, 1994,
Pascual-Marqui et al., 1999, 2002). Furthermore, these solutions were
normalized averaging any estimated dipole current density at each
voxel and frequency bin by themean of the dipole current density com-
puted across all frequencies (0.5–45Hz) and voxels of the brain volume.
This procedure of normalization typically ﬁts EEG power density into a
Gaussian distribution and reduces its inter-subject variability (Nuwer,
1988; Leuchter et al., 1993). After this normalization, the LORETA solu-
tions lost the original physical dimension andwere represented by arbi-
trary units. In this scale, the value “1” was equal to the mean of the
dipole current density at all frequencies (0.5–45 Hz) and voxels of the
brain volume.
In line with the intrinsic low-spatial resolution of LORETA solutions,
we developed a MATLAB software to average all LORETA solutions of
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terest (ROI). Speciﬁcally, we considered frontal, central, parietal, occip-
ital, temporal, and limbic ROIs in the LORETA brain compartment. Table
2 reports the list of BAs relative to any ROI used in the present study.
Finally, amain advantage of LORETA source estimation is that the re-
spective contribution of several cortical sources of scalp EEG rhythms
can be approximately disentangled. For example, EEG rhythms recorded
at scalp parietal electrodes are the summation of EEG activity generated
by parietal, occipital, and temporal source activity. LORETA uses amath-
ematical model of head taking into account the volume conductor ef-
fects and may disentangle the contribution of the difference cortical
sources of EEG rhythms recorded at scalp parietal electrodes.
2.7. Statistical analyses
Sixth main statistical sessions were performed by commercial tool
STATISTICA 10 (StatSoft Inc., www.statsoft.com).
The ﬁrst statistical session tested the hypothesis that the activity of
EEG cortical (LORETA) sources did differ between the Healthy and
naïve HIV groups. To this aim, an ANOVA used regional normalized
LORETA solutions at T0 as a dependent variable (p b 0.05). The
ANOVA factors were Group (Healthy, HIV; independent variable),
Band (delta, theta, alpha 1, alpha 2, alpha3, beta 1, beta 2), and ROI (cen-
tral, frontal, parietal, occipital, temporal, limbic). Mauchly's test evaluat-
ed the sphericity assumption. The degrees of freedomwere corrected by
Greenhouse–Geisser procedure when appropriate. The education was
used as a covariate. Duncan test was used for post-hoc comparisons
(p b 0.05 one-tailed). The hypothesiswould be conﬁrmed by the follow-
ing two statistical results: (i) a statistical interaction effect including the
factor Group (p b 0.05); and (ii) a post-hoc test indicating statistically
signiﬁcant differences between the normalized LORETA solutions with
the pattern Healthy ≠ naïve HIV (Duncan test, p b 0.05, one-tailed).
The second statistical session tested the hypothesis that the z-score
of the ratio between parietal delta and alpha 3 LORETA source activity
(i.e. the “EEG marker”) at T0 allows the identiﬁcation of a relatively
high percentage (about 40–50%) of naïveHIV individualswith statistical
abnormality of EEG activity. To this aim, z-score was calculated for the
EEG marker as follows:
z ¼ x−μ
σ
;
where “x” is the value of the EEG marker in a given naïve HIV subject;
“μ” is the mean of the EEG marker in the reference Healthy group; and
“σ” is the standard deviation of the EEG marker in that control group.
Overall, z-score indicates the probability that any given naïve HIV sub-
ject belongs to theHealthy group in terms of the EEGmarker. The statis-
tical threshold was set at p b 0.05, one-tailed. This means that a given
naïve HIV subject was considered as having a statistically deviant EEG
marker (“EEG+”) when z-score value of that EEG marker was higher
than the threshold of p b 0.05 (one-tailed)with reference to theHealthy
group. If this is not the case, naïve HIV individuals were denoted as
“EEG−” (i.e. statistically normal EEG marker).
The third statistical session tested the hypothesis that EEG+ status
is relevant for the assessment of naïve HIV subjects. To this aim, the
MMSE score, CD4 count, and VL at T0 were compared between theTable 2
Brodmann areas included in the cortical regions of interest (ROIs) of the present study.
LORETA Brodmann areas into the regions of interest (ROIs)
Frontal 8, 9, 10, 11, 44, 45, 46, 47
Central 1, 2, 3, 4, 6
Parietal 5, 7, 30, 39, 40, 43
Temporal 20, 21, 22, 37, 38, 41, 42
Occipital 17, 18, 19
Limbic 31, 32, 33, 34, 35, 36sub-group of naïve HIV subjects with EEG+ and the sub-group of
those with EEG− (Student test, p b 0.05 one-tailed). The working hy-
pothesis would be conﬁrmed by t-values indicating lower MMSE
score, lower CD4 count, and higher VL in the sub-group of naïve HIV
subjects with EEG+ than in the sub-group of those with EEG−
(p b 0.05 one-tailed).
The fourth statistical session tested the hypothesis that 5 months of
cART induces an improvement of global cognitive status and/or biolog-
ical markers in the two sub-groups of naïve HIV subjects (i.e. EEG+ and
EEG−). To this aim,MMSE score, CD4 count, and VL in the twoHIV sub-
groups were compared between T0 and T5 (Student test, p b 0.05 one-
tailed). The hypothesis would be conﬁrmed by t-values indicating
higher MMSE score, lower CD count, and higher VL at T5 than at T0
(p b 0.05 one-tailed; nonparametric test for the MMSE score).
The ﬁfth statistical session tested the hypothesis that 5 months of
cART induce a recovery of EEG cortical (LORETA) source activity only
in the sub-group of naïve HIV subjects with EEG+. To this aim, two
ANOVAs (one for the sub-group of naïve HIV subjects with EEG+ and
one for the sub-group of naïve HIV subjects with EEG−) were comput-
ed using regional normalized LORETA solutions as a dependent variable
(p b 0.05). The ANOVA factors were Time (T0, T5), Band (delta, theta,
alpha 1, alpha 2, alpha 3, beta 1, and beta 2), and ROI (central, frontal,
parietal, occipital, temporal, and limbic). Mauchly's test evaluated the
sphericity assumption. Correction of the degrees of freedom was made
with the Greenhouse–Geisser procedure when appropriate. Duncan
test was used for post-hoc comparisons (p b 0.05). The hypothesis
would be conﬁrmed by the following three results: (i) a statistical inter-
action effect including the factor Time (p b 0.05) for the sub-group of
naïve HIV subjects with EEG+; (ii) a post-hoc test indicating statistical-
ly signiﬁcant differences of the regional normalized LORETA solutions
with the pattern T0 ≠ T5 (Duncan test, p b 0.05, one-tailed) for the
sub-group of naïve HIV subjects with EEG+; and (iii) no statistical in-
teraction effect including the factors Time for the sub-group of naïve
HIV subjects with EEG−.
The sixth statistical session tested the hypothesis that the activity of
EEG cortical (LORETA) sources is related to biological markers of the
HIV. To address this issue, we performed a correlation analysis by Pear-
son test between normalized LORETA solutions and CD4 count in the
two sub-groups of −naïve HIV subjects (i.e. EEG+ and EEG−;
p b 0.05) at T0. The hypothesis would be conﬁrmed by a statistical cor-
relation (p b 0.05) in the sub-group of naïve HIV subjects with EEG+,
and no statistical correlation (p N 0.05) in the sub-group of naïve HIV
subjects with EEG−.
3. Results
3.1. Cortical (LORETA) sources of EEG rhythms estimated before the therapy
(T0): the Healthy vs. the naïve HIV group
Fig. 1 maps the grand average of the normalized LORETA solutions
(i.e., normalized dipole current density at cortical voxels) modeling
the distributed EEG cortical sources at delta, theta, alpha 1, alpha 2,
alpha 3, beta 1, and beta 2 bands in the Healthy group and in the
naïve HIV group before. These data refer to the period before the begin-
ning of the cART (T0). The Healthy group showed alpha 2 and alpha 3
sources with the highest activity in the occipital regions. Delta, theta,
and alpha 1 sources pointed to moderate activity when compared to
the alpha 2 and alpha 3 source activity. Finally, the beta 1 and beta 2
sources had the lowest activity. When compared to the Healthy group,
the naïve HIV group was characterized by higher parietal delta source
activity and lower posterior alpha 2 and alpha 3 source activity.
The ANOVA on the normalized LORETA solutions pointed to a statis-
tically signiﬁcant interaction (F(30, 3120)= 14.649, p b 0.0001) among
the factors Group (HIV and Healthy; independent variable), Band (beta
1, beta 2, alpha 1, alpha 2, alpha 3, theta, and delta), and ROI (frontal,
central, temporal, parietal, occipital, and limbic). Fig. 2 shows the
Fig. 1.Grand average of the normalized low-resolution brain electromagnetic tomography (LORETA) solutions (i.e. normalized dipole current density at the cortical voxels) modeling the
activity of distributed electroencephalographic (EEG) cortical sources at delta, theta, alpha 1, alpha 2, alpha 3, beta 1, and beta 2 bands in the Healthy and naïve HIV groups before the
therapy (T0). The normalization of the LORETA solutions was obtained by computing the ratio between the LORETA current density at each voxel with the mean of the current density
values averaged across all frequencies (0.5–45 Hz) and 2394 voxels of the brain source space. The color scale ranges from 0 to the maximum value of the normalized current density
estimated at alpha 2 frequency band.
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These solutions modeled the activity of the cortical sources of EEG
rhythms at the various frequency bands. In theﬁgure, the source activity
across the frequency bands has the shape of EEG relative power spectra.
Notably, proﬁle and magnitude of the source activity differed in the
naïve HIV group compared to the Healthy group. The highest values of
the source activity were observed in posterior cortical regions at high-
frequency alpha sub-bands (i.e. alpha 2 and 3). Duncan planned post-Fig. 2.Mean regional normalized LORETA solutions relative to a statistical ANOVA interaction (F
variable), Band (delta, theta, alpha 1, alpha 2, alpha 3, beta 1, beta 2), and ROI (central, frontalhoc testing showed that the parietal delta source activity was higher
in the naïve HIV group than in the control Healthy group (p b 0.005).
Furthermore, compared to the control Healthy group, the naïve HIV
group showed a lower alpha 1 source activity in the limbic region
(p b 0.05), as well as lower alpha 2 and alpha 3 source activity in parie-
tal, occipital, temporal, and limbic regions (p b 0.00005).
The present results conﬁrm that the parietal cortical sources of rest-
ing state eyes-closed delta and high-frequency alpha rhythms are(30, 3120)= 14.649, p b 0.0001) among the factors Group (HIV andHealthy; independent
, parietal, occipital, temporal, limbic).
Table 3
Means (±SE) of the demographic, clinical features, and neuropsychological data in a sub-
group of naïve HIV individuals with a statistically deviant EEGmarker (i.e. EEG+) and an-
other sub-group of naïve HIV individuals with a normal EEG marker (i.e. EEG−). All data
refer were collected before (T0) the beginning of a combined antiretroviral therapy
(cART). The third column reports the results of a statistical analysis (p b 0.05, one-tailed)
comparing the reportedmean values between the two sub-groups (i.e. EEG− vs. EEG+).
EEG− EEG+ p
values
N 24 24
Age (years) 36.8 (±2.2 SE) 39.4 (±1.6 SE) n.s.
Education (years) 13.6 (±0.4 SE) 12.8 (±0.8 SE) n.s.
MMSE score 29.2 (±0.3 SE) 27.7 (±0.4 SE) p =
0.01
IAF (Hz) 10.4 (±0.2 SE) 9.9 (±0.2 SE) p =
0.02
CD4 count (cells/μl) 443.2 (±44.1 SE) 305.2 (±46.5 SE) p =
0.01
VL (copies/ml) 65,030 (±313,807.7
SE)
175,303.5 (±61,198.2
SE)
p =
0.04
Trial making test A 37.2 (±2.8 SE) 37.5 (±2.8 SE) n.s.
Trial making test B 109.4 (±9.4 SE) 93.5 (±9.0 SE) n.s.
Trial making test B-A 71.6 (±7.8 SE) 56.6 (±7.3 SE) n.s.
Verbal ﬂuency for letter 34.1 (±2.4 SE) 33.0 (±2.2 SE) n.s.
Verbal ﬂuency for
category
44.2 (±2.1 SE) 41.4 (±1.8 SE) n.s.
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rophysiological assessment of naïve HIV patients before the beginning
of the cART. Fig. 3A represents the individual values of the ratio between
parietal delta and alpha-3 source activity (i.e. the EEG marker) in all
healthy and naïve HIV subjects before the therapy (i.e. T0). As expected,
the EEG marker showed higher values (as a trend towards EEG abnor-
malities) in the HIV group than the Healthy group.
Fig. 3B plots the z-score of the EEGmarker (i.e. the ratio between pa-
rietal delta and alpha-3 source activity) in the naïve HIV subjects before
the therapy (T0). In the ﬁgure, the dashed horizontal separation line in-
dicates the threshold of the statistical difference (p b 0.05 one-tailed)
that splits all naïve HIV individuals into the following two sub-groups:
the sub-group of the naïve HIV subjects with a statistically deviant
EEG marker (i.e. EEG+, above the horizontal separation line) and the
sub-group of those with a normal EEG marker (i.e. EEG−, below the
horizontal separation line). Interestingly, there was a relatively high
percentage (i.e. 50%) of the naïve HIV subjects with z-score values indi-
cating a statistically deviant EEG marker (i.e. EEG+).
Fig. 3C draws the scatterplot between the z-score at T0 and T5 for all
naïve HIV individuals. In this ﬁgure, the diagonal separation line divided
the naïve HIV individuals showing a reduction (above the diagonal line
those with an improvement of the EEG marker at T5) vs. an increase
(down the diagonal line those with a worsening of the EEG marker at
T5) in the z-score after 5months of cART. Note the symmetrical and ho-
mogenous distribution of the naïve HIV individuals around the diagonal
line until z-score values of about 2.5, suggesting a Gaussian distribution
of the cART effects on the EEGmarker. Instead, therewas a prevalence of
the naïveHIV individuals down the diagonal linewith the z-score values
higher than about 2.5, pointing to a beneﬁcial effect of the cART on the
EEG marker in the majority of those naïve HIV individuals.
Table 3 reports the values of a statistical analysis (p b 0.05, one-
tailed) computed to evaluate the differences between the two sub-
groups of the naïve HIV subjects (i.e. EEG+ and EEG−) for eachFig. 3. A) Individual values of the EEGmarker in all naïve HIV (before the therapy, T0) and
healthy subjects. This EEG marker was deﬁned as the ratio between parietal delta and
alpha-3 source activity. The EEG source activity was estimated by the LORETA software.
Speciﬁcally, this software estimated dipole current density in regions of interest of an
average model of the human cerebral cortex (see the Methods). B) z-Score of the EEG
marker in all naïve HIV individuals. The z-score values were computed using a control
Healthy group as a normative reference. Dashed horizontal separation lines indicate the
threshold of a statistical difference (p b 0.05, one-tailed) that splits all naïve HIV subjects
in two sub-groups at T0: the sub-group of the naïve HIV individuals with a statistically
deviant EEG marker (i.e. EEG+, above the line) and the sub-group of those with a
normal EEG marker (i.e. EEG−, below the line). C) Scatterplot between the z-score at T0
and T5 in all naïve HIV subjects. In the scatterplot, the naïve HIV individuals with EEG−
and EEG+ are represented as yellow and red circles, respectively.dependent variable of interest, namely the age, education, MMSE
score, IAF, CD4 count, VL, Trial making test A, Trial making test B, Trial
making test B–A, and Verbal ﬂuency for letter and category. Mann–
Whitney U test was used for theMMSE score, and t-test for the remain-
ing variables (p b 0.05). Results showed that compared with the naïve
HIV sub-groupwith EEG−, the naïve HIV sub-groupwith EEG+ exhib-
ited a lower global cognitive status, as revealed by theMMSE score, and
abnormal serological indexes such as lower CD4 count and higher VL
(p b 0.05). The other variables showed no statistical difference
(p N 0.05).3.2. Effects of cART on clinical markers and cortical (LORETA) sources of EEG
rhythms
Table 4 reports the values of t-tests comparing the IAF, CD4 count,
and VL between T0 (i.e. before the therapy) and T5 (i.e. after 5 months
of therapy) in the naïve HIV sub-group with EEG+ and that with
EEG−. For the MMSE score, that table reports the results of the
Wilcoxon test (p b 0.05). FromT0 to T5, the twoHIV sub-groups showed
an improvement in the serological indexes. Namely, there was a higher
CD4 count and a lower VL (p b 0.05) at T5 than T0.Table 4
Means (±SE) of the clinical features of the two sub-groups of treatment-naïve HIV sub-
jects (i.e. EEG+and EEG−) before (T0) and after 5months of cART (T5). The third column
reports the results of t-tests (p b 0.05, one-tailed) comparing these mean values between
the pre-treatment and follow up (i.e. T0 vs. T5).
T0 T5 p values
EEG−
MMSE score 29.2 (±0.3 SE) 29.0 (±0.4 SE) n.s.
IAF (Hz) 10.4 (±0.2 SE) 10.1 (±0.2 SE) n.s.
CD4 count
(cells/μl)
443.2 (±44.1 SE) 561.9 (±57.8 SE) p = 0.0004
VL (copies/ml) 65,030 (±313,807.7 SE) 23.6 (±7.3 SE) p =
0.00005
EEG+
MMSE score 27.7 (±0.4 SE) 27.3 (±0.4 SE) n.s.
IAF (Hz) 9.9 (±0.2 SE) 10.1 (±0.2 SE) n.s.
CD4 count
(cells/μl)
305.2 (±46.5 SE) 438.9 (±47.4 SE) p = 0.0001
VL (copies/ml) 175,303.5 (±61,198.2 SE) 41.7 (±11.9 SE) p = 0.004
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tions (i.e., normalized dipole current density at cortical voxels) model-
ing the EEG source activity at delta, theta, alpha 1, alpha 2, alpha 3,
beta 1, and beta 2 bands in the two HIV sub-groups (i.e. EEG+ and
EEG−). These LORETA solutions referred to both T0 and T5. The HIV
sub-group with EEG+ was characterized by a decrement of the delta
source activity from T0 to T5 in widespread cortical regions. In parallel,
there was a slight increase of alpha source activity from T0 to T5 in pos-
terior regions. On the contrary, the HIV sub-group with EEG− showed
similar EEG source activity at T0 and T5. This effect was true at all fre-
quency bands. Of note, the alpha source activity was quite higher in
the HIV sub-group with EEG− than in that with EEG+. This difference
was expected based on the criterion (the z-score of the EEG marker)
used for the formation of the two sub-groups of HIV subjects. It is irrel-
evant for the following statistical comparisons due to the “within” de-
sign of the planned ANOVAs in the two sub-groups of HIV subjects.
In the sub-group with EEG+ before the therapy (N = 24), the
ANOVA on the regional normalized LORETA solutions showed a statisti-
cally signiﬁcant interaction (F(30, 690) = 3.187, p b 0.0001; see Fig. 5
bottom) among the factors Time (T0, T5), Band (delta, theta, alpha 1,
alpha 2, alpha 3, beta 1, beta 2), and ROI (frontal, central, temporal, lim-
bic, parietal, occipital). Duncan planned post-hoc testing showed that
comparedwith T0, T5was associated with increased delta source activ-
ity in central, frontal, parietal, occipital, temporal, and limbic regions
(p b 0.005). Itwas also related to increased limbic alpha 1 source activity
(p b 0.05). Furthermore, there was an increase of source activity in pa-
rietal, occipital, and limbic alpha 2 and alpha 3 regions (p b 0.05). The
ANOVA also showed a statistically signiﬁcant interaction (F(6, 138) =
4.1882, p b 0.0005) between the factors Time and Band. Duncan
planned post-hoc testing showed that compared to T0, T5was associat-
edwith an increased delta activity inwidespread sources (i.e. regardless
the factor ROI) in the HIV subgroup with EEG+ (p b 0.005).
An exploratory correlation analysis (Pearson test, p b 0.05) was per-
formed between the some EEG variables of interest (i.e. global delta,Fig. 4. Grand average of the normalized LORETA solutions modeling the distributed EEG cortica
groups of treatment-naïve HIV individuals (i.e. EEG+ and EEG−) before (T0) and after 5month
density estimated at alpha 3 frequency band.posterior alpha-3 source activity, and parietal delta/alpha-3 source ac-
tivity) and the serological variables (i.e. viral load and CD4 count) before
the therapy, when there was no interference of the cART. Results
showed a statistically signiﬁcant correlation only between the global
delta source activity and the CD4 count (r=−0.51; p= 0.01), possibly
due to a high inter-subject variability in the alpha source activity in the
HIV subjects (Fig. 6).
In the sub-group with EEG− (N = 24), the ANOVA on the regional
normalized LORETA solutions showed no statistically signiﬁcant effect
of the cART (p N 0.05; see Fig. 5 top). To further control about the lack
of a relationship between EEG source activity and HIV in these subjects,
an exploratory correlation analysis (Pearson test, p b 0.05) was per-
formed between some EEG variables of interest (i.e. global delta, poste-
rior high-frequency alpha, and parietal delta/alpha-3 source activity)
and the serological variables (i.e. viral load and CD4 count) before the
therapy. Results showed no statistically signiﬁcant correlation between
these variables (p N 0.05).
In Fig. 7, some diagrams plot the z-score of the EEG marker (i.e. pa-
rietal delta/alpha-3 source activity) in thenaïveHIV individuals (circles)
of the two EEG+ and EEG− sub-groups before (T0) and after 5months
of cART (T5). Overall, most naïve HIV individuals with EEG− showed a
quite stable z-score from T0 to T5 (Fig. 7A)while several naïve HIV peo-
plewith EEG+unveiled a reduced z-score fromT0 to T5 (Fig. 7B). In Fig.
7, other diagrams draw the scatterplots between the z-score at T0 and
T5 in the naïve HIV individuals with EEG+ and EEG−. The naïve HIV
persons with EEG− showed a symmetrical distribution around the di-
agonal separation line (Fig. 7C), indicating a Gaussian impact of the
cART on the z-score. In contrast, most of the naïve HIV individuals
with EEG+ were located down the diagonal separation line (Fig. 7D),
pointing to an apparent reduction in the z-score at T5 (i.e. trend towards
the normalization of the EEGmarker). Other diagrams of the Fig. 7 illus-
trate the scatterplots between the z-score at T0 and the difference in the
z-score between T5 and T0 (i.e. T5 minus T0) as an index of the change
due to the therapy. The horizontal separation lines divide the naïve HIVl sources at delta, theta, alpha 1, alpha 2, alpha 3, beta 1, and beta 2 bands in the two sub-
s of cART (T5). Color scale ranges from 0 to themaximum value of the normalized current
Fig. 5. Top: Mean regional normalized LORETA solutions relative to a statistically non-signiﬁcant ANOVA interaction (p N 0.9) among the factors Time (T0, T5), Band (delta, theta, alpha 1,
alpha 2, alpha 3, beta 1, beta 2), and ROI (central, frontal, parietal, occipital, temporal, limbic) for the sub-group of treatment-naïve HIV subjects with a normal EEG marker (i.e. EEG−).
Bottom:Mean regional normalized LORETA solutions relative to a statistically signiﬁcant ANOVA interaction (F(30, 3120)= 14.649, p b 0.0001) among the factors Time, Band, and ROI for
the sub-group of treatment-naïve HIV subjects with a statistically deviant EEG marker (i.e. EEG+).
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vs. an increase (above the horizontal line) in the z-score after 5 months
of cART. Note that the naïve HIV individuals with EEG− (Fig. 7E) were
symmetrically and homogenously distributed around the horizontal
separation line, indicating a Gaussian distribution of the cART effect on
the z-score. In contrast, most of the naïve HIV individuals with EEG+
(Fig. 7F) were located down the horizontal separation line, pointing to
a prominent reduction in the z-score at T5 (i.e. trend towards the nor-
malization of the EEG marker).
The statistical analyses conﬁrmed the above readouts. A Fisher-test
showed that the T5 minus T0 variance was greater in the naïve HIV in-
dividuals with EEG+ than those with EEG+ were (p b 0.0001).Furthermore, a t-test unveiled that the T5 minus T0 values were more
negative (greater z-score reduction) in the former than the latter HIV
group (p b 0.05). Moreover, 49% (N= 11) of the naïve HIV individuals
with EEG+ (N = 24) changed to EEG− at T5 (Fig. 3C bottom-right
quadrant) while only 8% (N = 2) of those with EEG− (N = 24) did
(Fig. 3C top-left quadrant). These converging ﬁndings suggest that
5 months of cART reduced the z-score (normalized the EEG marker)
much more in the naïve EEG individuals with EEG+ than those with
EEG− did. Indeed, the naïve EEG individuals with EEG+ but not
EEG−were supposed to be sensitive to the therapy.
The above results showed that therewere two naïve HIV sub-groups
of particular interest, namely the EEG+ subjects who recovered to
Fig. 6. Scatterplot between the global delta LORETA current density and the CD4 count
before the therapy in the naïve HIV subjects with a statistically deviant EEG marker (i.e.
EEG+).
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of 24). How did these HIV sub-groups contribute to the difference T5
minus T0 in the CD4 count and VL in the global HIV group (Table 4)?
To address this issue, two control t-tests were performed (p b 0.05).
The respective dependent variables were the difference T5 minus T0
in the CD4 count and VL. For the VL, there was a greater difference T5
minus T0 (i.e. decrease) in the EEG+ recovered to EEG− than the
EEG+ stable (p = 0.01). This ﬁnding suggests that most of the VL re-
duction in thewhole HIV groupwasdriven by the EEG+subjects recov-
ered to EEG−. For the CD4 count, no statistical effect was observed
(p = 0.3), indicating that the recovered CD4 count in the whole HIV
group was driven by both HIV sub-groups, namely the subjects withFig. 7.A) z-Score of the EEGmarker in all naïve HIV subjectswith EEG− at baseline (T0) and aft
at T0 and T5. C) Scatterplot of the z-score at T0 and T5 in all naïve HIV subjects with EEG−. D) S
the z-score at T0 and T5 minus T0 (T5–T0) in all naïve HIV subjects with EEG−. F) ScatterplotEEG+ recovered to EEG− and thosewith a stable EEG+. This statistical
design was not used for the naïve EEG− subjects as practically all
remained EEG− at T5 (i.e. N = 22 out of 24).
3.3. Control analyses
To cross-validate LORETA cortical source estimates, we performed a
control analysis at T0 by computing topographic maps of EEG power
density for the most representative bands of interest (i.e. delta, alpha
2 and alpha 3) for the Healthy and the naïve HIV groups, separately
(Fig. 8). In line with normalization procedure used for LORETA source
estimation, EEG power density at each scalp electrode was normalized
to EEG power density averaged across all frequencies (0.5–45 Hz) and
across all electrodes (N = 19). Fig. 9 plots the statistical t maps of
scalp EEG power density for delta, alpha 2 and alpha 3, respectively.
These maps showed the statistical differences of the EEG power density
between the Healthy and the naïve HIV group. Although these results
globally conﬁrmed the differences between the two groups based on
the comparison of the corresponding LORETA cortical source estimates,
the spatial resolution of EEG power density mapped at scalp level ap-
peared to be lower than that at source level.
4. Discussion
Previous evidence indicated that HIV patients showed a beneﬁcial
cART effect on brain function (Clifford, 2008) as reduction in the VL
and an increase in the CD4 cell count (Graham et al., 1992; Hammer
et al., 1997; Hunt et al., 2003; Williams et al., 2012; Babiloni et al.,
2014). Furthermore, we demonstrated that before the cART, abouter 5months of cART (T5). B) z-Score of the EEGmarker in all naïve HIV subjects with EEG+
catterplot of the z-score at T0 and T5 in all naïve HIV subjects with EEG+. E) Scatterplot of
of the z-score at T0 and T5 minus T0 (T5–T0) in all naïve HIV subjects with EEG+.
Fig. 8. Spatial distribution of EEG power density for most representative EEG bands (i.e.
delta, alpha 2 and alpha 3) at baseline (T0) and for the Healthy and the naïve HIV.
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normal activity of parietal cortical sources of resting state delta and
high-frequency alpha rhythms (Babiloni et al., 2015b). Such abnormal-
ity was deﬁned as the z-score of the ratio between the parietal delta and
high-frequency alpha source activity in any individual naïve HIV male
with respect to a reference group of healthy subjects. This ratio, then,
was proposed as an EEG marker for the neurophysiological assessment
of naïve HIV male subjects before the therapy (Babiloni et al., 2015b).
Results of the present study conﬁrmed those reported in a reference
previous research in HIV individuals (Babiloni et al., 2015b). Compared
with theHealthy group, the naïveHIV group pointed to a decrease in the
low- andhigh-frequency (i.e. alpha 2 and alpha 3) source activity in sev-
eral cortical regions (i.e. parietal, occipital, temporal and limbic regions).
In contrast, the increase in the delta (i.e. parietal) and the decrease in
the low-frequency alpha (i.e. limbic) source activity were regionally
circumscribed. Of note 50% (N = 24) of the present naïve HIV subjects
pointed to a z-score indicating a deviant EEGmarker (i.e. EEG+) before
the therapy.
At this early stage of the research, we can just speculate about the
clinical neurophysiological meaning of these effects. Resting state
eyes-closed alpha rhythms in healthy humans are prominent in wide-
spread posterior cortical regions, especially in visuospatial and
somatomotor areas (Pfurtscheller and Lopez da Silva, 1999). TheseFig. 9. Topographical maps of statistical values at electrode (sensor) level for frequency
bands that presented at baseline most statistical signiﬁcant differences between Healthy
and naïve HIV groups (i.e. delta, alpha 2 and alpha 3).rhythms are generated because of the cortical neural synchronization
in distributed pyramidal neurons, which regulates low brain arousal
and vigilance. This effect of synchronization actively inhibits the cere-
bral cortex, andmay depend on the efﬁciency of the signal transmission
and functional connectivity within cerebral neural networks involving
the basal forebrain, ascending neurotransmitter systems, thalamus,
and cerebral cortex (Pfurtscheller and Lopez da Silva, 1999). The func-
tional meaning of low- and high-frequency alpha rhythms is supposed
to be different. Low-frequency alpha rhythms (i.e. alpha 1 and alpha
2) may subserve subject's global arousal and alertness while high-fre-
quency alpha rhythms (i.e. alpha 3) may reﬂect the event-related oscil-
lation within peculiar neural systems engaged in the elaboration of
semantic or sensorimotor information (Klimesch et al., 1998;
Klimesch, 1999). Keeping in mind this theoretical premise, the present
results hint that the naïve HIV subjects with EEG+ were characterized
by a widespread alteration in the neural systems oscillating in broad
posterior cortical regions that underpin several cognitive functions
such as attention, sensorimotor, and semantic information processing.
Instead, a prominent decrease in the lower-frequency alpha rhythm
(i.e. alpha 1) was localized in the limbic region, and it might be associ-
atedwith the regulation of global brain arousal and alertness. Limbic re-
gion includes anterior and posterior cingulate cortices and medial
prefrontal cortex (BA 31, 32 and 33), which are part of the so-called de-
fault mode network (DMN). Previous evidence has shown that DMN
operates to maintain a cortical idling and plays a causal role in the en-
hancement of dominant low-frequency alpha rhythms in quiet wake-
fulness (Capotosto et al., 2014).
As mentioned above, the present ﬁnding showed a noticeable in-
crease in the delta source activity localized in theparietal region. This ef-
fect might be associated with vascular lesions in the periventricular
white matter, which were found to affect neurotransmission from sub-
cortical to parietal regions in patients with cerebrovascular lesions and
cognitive deﬁcits (Leuchter et al., 1994). Future research should evalu-
ate if naïve HIV subjects with EEG+ suffer from this kind of vascular le-
sions. In previous studies, HIV patients, especially those with cognitive
deﬁcits, were characterized by a white matter hyperintensity in MRIs
as a reﬂection of similar cerebrovascular lesions (Thurnher and
Donovan Post, 2008).
As a novelty of the present study, here we tested the hypothesis that
naïve HIV individuals with z-score indicating a deviant EEGmarker (i.e.
EEG+), but not HIV patients with normal EEG marker (EEG+), would
show a normalization of the EEG source activity after 5 months of
cART. This novel hypothesis was grounded on the concept that z-scores
of an adequate EEG marker would be sensitive not only to HIV's detri-
mental effects on brain function, but also to the beneﬁcial effects of
cART. Indeed, the present naïve HIV subjects exhibited beneﬁcial effects
after 5 months of cART in both delta and high-frequency alpha source
activity, although themajor effect was observed on the former. Namely,
the delta source activity decreased, while the high-frequency alpha
source activity increased.
Importantly, as a further novelty, we report that almost half (49%) of
these HIV individuals with EEG+ showed a statistical normalization of
the proposed EEGmarker (z-score) after 5 months of cART. Notably, no
statistical difference was found before and after the therapy in the HIV
patients with EEG−. Overall, these ﬁndings extend previous evidence
suggesting that the beneﬁcial cART effects on brain function are signiﬁ-
cant only in HIV patients with deviant EEG marker before the therapy.
An interesting result of the present study was the cART pronounced
effect on delta source activity in the naïve HIV individuals with EEG+
status prior to therapy. A tentative explanation can be based on the
physiological meaning of resting state delta rhythms in human subjects.
These rhythms are negligible in the physiological condition of relaxed
wakefulness, in contrast to dominant amplitude of posterior cortical
alpha rhythms (Babiloni et al., 2006b; Klimesch, 1996, 1999; Klimesch
et al., 1997, 1998; Pfurtscheller and Lopez da Silva, 1999). Nevertheless,
it has been proposed that cortical association areas physiologically
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cessing across widely spatially distributed neural assemblies (Nuñez,
1995). In this line, delta rhythms have been correlated positively with
cortical metabolism in normal subjects, as revealed by
ﬂuorodeoxyglucose positron emission tomography (Sadato et al.,
1998; Alper et al., 2006). On the other hand, cortical delta rhythms
have shown an abnormal high power in patients with cognitive impair-
ment such as Alzheimer's disease, cerebrovascular disease, and
Parkinson's disease (Babiloni et al., 2004, 2006b, 2011b). In those with
mild cognitive impairment and Alzheimer's disease, these abnormal
delta rhythms were associated with white matter vascular lesions
(Babiloni et al., 2011c), atrophy of hippocampus and cortical gray mat-
ter (Babiloni et al., 2010, 2013), and cortical hypometabolism
(Rodriguez et al., 2004). Taking together these studies and the present
data, we posit that such deviant activity of widespread delta cortical
sources reﬂects both theHIV impact on brain function and the beneﬁcial
effects of cART. The underlying clinical neurophysiological mechanisms
have yet to be fully elucidated. Neuronal-glia and inﬂammatorymarkers
due to HIV might be associated with cerebrovascular, metabolic, and
structural changes, as recently shown in vivo in humans by
ﬂuorodeoxyglucose positron emission tomography (Sathekge et al.,
2014) as well as spectroscopic (Sailasuta et al., 2015), structural (Li et
al., 2014), and functional (Chang et al., 2013)magnetic resonance imag-
ing (MRI). In this line of reasoning, these changes might partially derail
neural synchronization mechanisms and induce a partial “disconnec-
tion mode” of the cerebral cortex (Babiloni et al., 2014).
Keeping inmind the above data and considerations, onemight argue
that brain atrophy may have an unpredictable impact on the EEG corti-
cal source estimation with a normal average brain model as that imple-
mented in the LORETA freeware. Indeed, a ﬁne EEG cortical source
estimation should use a brain source model adapted to the individual
cerebral atrophy. Furthermore, it should use a high spatial sampling of
the potential distribution over the scalp (i.e. 64–128 electrodes). How-
ever, we think that the present methodological approach was adequate
for an exploratory study for the following reasons. In the naïve HIV sub-
jects of this study, the magnitude of the brain atrophy is expected to be
low, although it can derange the cortical neural synchronization mech-
anisms generating rsEEG rhythms. In this line, the global cognitive per-
formance, as revealed by theMMSE score, was signiﬁcantly lower in the
HIV group than thematched control group. However, the HIV group ex-
hibited a global cognitive performance within the inferior normal limit,
on average. This quasi-normal cognitive status in the HIV group may be
associated with an initial phase of the HIV neuroinvasion. At that initial
phase, the effects of the HIV neuroinvasion may be not so disruptive to
producemarkedwhitematter vascular lesions and grey matter atrophy
(Thurnher and Donovan Post, 2008; Peluso et al., 2012; Gottumukkala
et al., 2014) to alter signiﬁcantly themacroscopic volume of the cortical
sources generating rsEEG rhythms. The impact of the brain atrophymay
be furtherlymitigated from the expectedwidespread distribution of the
rsEEG potential distributions. Indeed, several independent research
groups have shown that rsEEG rhythms are generated by largely distrib-
uted cortical sources whose EEG activity can be recorded by 10–20
montage system without spatial aliasing. For this reason, several inde-
pendent research groups used LORETA cortical source estimation from
EEG data collected by a relatively low spatial sampling with 19 elec-
trodes of 10–20 system (Anderer et al., 2000, 2003, 2004; Babiloni et
al., 2004, 2006a, 2006b, 2006c, 2006d, 2006e; Laufer and Pratt, 2003a,
2003b; Mulert et al., 2001; Veiga et al., 2003;Winterer et al., 2001). Ac-
cording to the theory of the signal sampling, a temporal or spatial sam-
pling should be higher than the spatial and temporal (frequency)
information content of the signal to be recorded, to avoid the so-called
aliasing (i.e. a distortion in the signal reconstruction). The present
methodology may ﬁt this theory. It can be assumed that rsEEG rhythms
have a low spatial information content due to a widespread cortical
neural synchronization underpinning a low brain arousal and vigilance
in a condition of quiet wakefulness. In the present study, wecorroborated this assumption with the results of a control analysis per-
formed to cross-validate the LORETA cortical source estimation. In that
analysis, the spectral variables were computed from the rsEEG rhythms
at the sensor (electrode) level. The results conﬁrmed those obtained at
the cortical source level. Overall, topographically widespread cortical
sources of delta and alpha rhythms reﬂected neurophysiologic abnor-
malities in HIV patients, at least at the group level. It was concluded
that the use of a normal brain source model and a traditional 10–20
electrode montage was adequate for this exploratory study, due to the
general low spatial information content in the rsEEG rhythms and the
expected low brain atrophy in the present naïve HIV subjects. However,
future conﬁrmatory studies should useMRI-based realistic headmodels
in naïve HIV subjects for an EEG cortical source estimation performed
from rsEEG rhythms recorded using 64–128 scalp electrodes.
4.1. Speciﬁcity and clinical signiﬁcance of the present results
An important remaining issue at present regards the speciﬁcity of
cART impact on the parietal delta/alpha 3 EEG marker. The current
study design prevents a deﬁnitive conclusion, as we did not have access
to repeated EEG recordings in HIV subjects not receiving cART and con-
trol healthy subjects. However, two ﬁndings support a preliminary pos-
itive answer to this question. Indeed, the naïve HIV individuals showing
a normal EEG marker before the therapy (i.e. EEG−) did not exhibit al-
tered EEG source activity after 5months of cART. Furthermore, such EEG
marker was not correlated with the CD4 count. These ﬁndings suggest
that the z-score procedure can detect not only the cases in which HIV
produces deviant EEG source activity but also the cases in which HIV
does not produce these effects. These ﬁndings support the idea that
the present procedure can unveil the pathological effects of HIV on the
neural synchronization mechanisms of cerebral cortex generating rest-
ing state EEG rhythms.
Another issue of the present results is about the clinical signiﬁcance
of the cART impact on the parietal delta/alpha 3 EEG marker. The pres-
ent results suggest that the z-score of the EEGmarkermay enrich the in-
strumental multifaceted assessment of naïve HIV individuals. This
marker should not be considered surrogate index of cognitive impair-
ment in naïve HIV individuals, as the neuropsychological and neuro-
physiological dimensions of the subject's assessment are
complementary rather than overlapping and redundant. These two di-
mensions explore different levels of brain functioning, namely neuro-
physiological mechanisms and cognitive performance. In this
theoretical framework, the z-score of the EEG marker estimated before
and after the cARTmay be useful to monitor the effect of the therapy on
brain function in naïve HIV individuals. This neurophysiological assess-
ment can provide additional useful information for the personalized
clinical management of the patient. Let us consider the following exam-
ple with two naïve HIV subjects after 5 months of cART: Both subjects
were EEG+ before the therapy and had similar values in MMSE, auton-
omy in the daily life, and cognitive reserve as indexed by education
years and intellectual occupations across the lifespan. One subject's
EEG marker status changed from EEG+ to EEG− at the follow-up,
while the other subject remained EEG+ at follow-up. The evaluation
of the EEG marker would suggest that, compared to the HIV subject
who recovered to EEG− status after therapy, the HIV subject who
remained in the EEG+ status should receive more neuroprotective
therapeutic resources and clinical attention to address his cART-resis-
tant neurophysiological “frailty”.
Finally, other issues were the recording of the EEG rhythms at only
two time-points (pre-treatment and follow-up), with a relatively
short follow-up (5 months), and an undetermined lengthiness of the
HIV infection at the date of the pre-treatment EEG recording. It would
be important to demonstrate a ﬁne-grain time-course of the EEGmark-
er in association with clinical evolution of the infection and cognitive
status, especially in the naïve HIV subjects with pre-treatment EEG+.
In these individuals, it can be hypothesized that the HIV infection was
155C. Babiloni et al. / NeuroImage: Clinical 12 (2016) 144–156longer when compared to those with pre-treatment EEG−. Unfortu-
nately, we could not test that hypothesis in the present study. We just
knew the time of the serological diagnosis of HIV, which does not reli-
ably reﬂect the time of the HIV infection. In several cases, that diagnosis
is incidental. Furthermore, the event of theHIV contagion could not nec-
essarily correspond to the episode told by the subject.
Keeping in mind the above considerations, future research should
aim at testing the EEGmarker with serial follow-ups across years, espe-
cially in the naïve HIV subjects with pre-treatment EEG+. Furthermore,
we encourage the quest for the individual clinical cases in whom the
event of the HIV contagion can be ascertained for the application of
the present methodological approach.
5. Conclusions
In the present study, we computed the z-score (p b 0.05, one-tailed)
of an EEG marker to monitor the effects of 5 months of cART on brain
function in naïve HIV (male) individuals with respect to a reference
group of healthy subjects. The EEG marker was deﬁned as the ratio be-
tween parietal delta and high-frequency alpha source activity. Before
the therapy, the z-score of the EEG marker was statistically deviant
(EEG+) in 50% of the naive HIV individuals. In this HIV sub-group
with EEG+, delta source activity decreased, while high-frequency
alpha source activity increased after 5 months of therapy. Furthermore,
N40% of them showed a normalized EEGmarker (EEG−) at that follow-
up. These results suggest that this statistical procedurewas able to iden-
tify treatment-naïve HIV single individuals with a deviant EEG source
activity before the cART. Furthermore, it was able to monitor the nor-
malization of this EEG source activity after 5 months of therapy in
many of them.
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